We recently reported that adolescents and young adults (AYAs) with B-cell ALL receiving allogeneic hematopoietic cell transplantation (allo-HCT) have inferior survival compared with children, primarily because of greater TRM. We therefore hypothesized that in the setting of allo-HCT for AML, similar inferior outcomes would be observed in AYA patients as compared with children. We reviewed outcomes of 168 consecutive patients (ages 0-30 years) with AML undergoing allo-HCT at our institution. Of these, 60% (n ¼ 101) were o15 years of age and 40% (n ¼ 67) were AYAs (15-30 years of age). We identified no significant differences in 5-year overall survival (48% vs 50%, P ¼ 0.89), disease-free (47% vs 47%, P ¼ 0.89), relapse (24% vs 33%, P ¼ 0.30) or TRM (27% vs 16%, P ¼ 0.10) between the two groups. However, AYA patients had a greater incidence of grade II-IV acute (48% vs 31%, P ¼ 0.01) and chronic GVHD (22% vs 7%, Po0.01). Based on this analysis we identified no differences in survival, relapse or TRM between AYAs and children with AML receiving allo-HCT.
INTRODUCTION
Gradual improvements in the survival of patients with newly diagnosed AML have been achieved through treatment intensification;
1,2 however, differences in outcomes continue to exist between adolescents and young adults (AYAs) and younger-aged children. 3, 4 Although overall survival appears to be similar between these two age groups (children o15 years of age vs AYAs), there are stark differences in chemotherapy-related mortality, with AYA patients having significantly higher rates of treatment-related deaths most often from infection. 3, 4 The reasons why AYA patients may have significantly worse outcomes compared with younger children include: age-related differences in the underlying cancer biology; 5 access to medical care; 6 compliance with treatment, 7 participation in clinical trials 8 and/or not receiving care at centers with AYA experience. 7, 9 We recently investigated survival differences between AYA patients and younger-aged children (o13 years of age) with B-cell ALL who received allogeneic hematopoietic cell transplantation (allo-HCT) at our institution and found significantly inferior survival in the AYA group. 10 These findings were primarily because of greater TRM in AYA patients. Based on these results and the higher mortality recently reported in chemotherapy-treated AYA AML patients, 3, 4 we hypothesized that AML AYA patients undergoing allo-HCT would have inferior outcomes as compared with younger patients.
PATIENTS AND METHODS

Study design and patient characteristics
A total of 168 AML patients, ages 0-30 years, underwent a myeloablative allo-HCT at the University of Minnesota between 1995 and 2010 (Table 1) .
Patients who received a nonmyeloablative allo-HCT or a prior allo-HCT were excluded from this analysis. Clinical and laboratory data were systematically and prospectively collected on all our patients undergoing allo-HCT and entered into the University of Minnesota Blood and Marrow Transplant Database. All patients and/or their parents or guardians signed consent to participate on institutional review board-approved transplant protocols and outcomes were reviewed retrospectively. The institutional review board reviewed and approved this study.
For the purpose of this analysis, we defined the AYA age group as 15-30 years. 6, 11, 12 In all, 101 (60%) patients were o15 years at the time of allo-HCT and 67 (40%) were 15-30 years of age (AYA). The median age at the time of allo-HCT for those o15 years of age was 8.1 (range, 0.5-14.99 years) as compared with 22.6 (range, 15.0-29.7 years) for the AYA. The median follow-up was 6.09 (range, 0.56-14.22) years after HCT for patients o15 years old and 5.75 (range, 1.84-12.46) years for AYA. Before transplant, 39 (39%) patients o15 years old were in first CR (CR1), 35 (35%) in second CR (CR2) and 27 (27%) in third CR (CR3) as compared with 32 (48%) in CR1, 25 (37%) in CR2 and 10 (15%) in CR3 for the AYA group (P ¼ 0.18).
Time from initial diagnosis to transplant was similar between the two groups, with a median of 219 (range, 67-1493) days for patients o15 years of age and 174 (range, 67-1653) days for AYA (P ¼ 0.93). There was no difference in exposure to CMV before transplant between younger patients and AYA (60% vs 55%, P ¼ 0.51). Twenty-eight patients (27.7%) o15 years old had high-risk cytogenetics with fms-like tyrosine kinase 3/internal tandem duplication (n ¼ 6), mixed lineage leukemia (11q23) rearrangements (n ¼ 22) and/or monosomy 5 or 7 (n ¼ 5) compared with 11 (16.4%) of the AYA (fms-like tyrosine kinase 3/internal tandem duplication, n ¼ 3; mixed lineage leukemia, n ¼ 8; and/or monosomy 5/7, n ¼ 5; P ¼ 0.12).
Donor selection and conditioning regimens
Stem cell sources included HLA matched related donor BM, matched unrelated donor BM, matched related PBSC and unrelated umbilical cord 1 blood (UCB). More than half of the patients o15 years old (n ¼ 60, 59.4%) received unrelated UCB, with the remaining receiving either matched related donor BM (n ¼ 10, 9.9%), matched unrelated donor BM (n ¼ 26, 25.7%) or matched related PBSC (n ¼ 5, 4.9%) compared with AYA patients where 33 (49.3%) received UCB, 11 (16.4%) matched related donor BM, 10 (14.9%) matched unrelated donor BM and the remaining 13 (19.4%) matched related PBSC (P ¼ 0.19). There was a significant difference between AYA and younger patients in terms of receiving double UCB units, with more AYAs receiving two units (76% vs 45%, Po0.01). This difference is consistent with our institutional cord blood selection criteria, where older patients are more likely to weigh more and require greater cell doses provided by two cord blood units. 13 The majority of patients (n ¼ 133, 79.2%) received myeloablative conditioning consisting of CY (120 mg/kg), TBI (1320 cGy) ± fludarabine (75 mg/m 2 ). The remaining patients received BU/CY, BU/melphalan, BU/ melphalan±fludarabine or CY/ATG/TBI. GVHD prophylaxis was primarily cyclosporine based (n ¼ 155, 86.3%), with T-cell depletion by elutriation in 10 patients (6%) and MTX only in 13 patients (7.7%).
Statistical methods
Five outcomes were studied: OS, disease-free survival (DFS), TRM, GVHD and relapse. The Kaplan-Meier method was used to estimate OS and DFS, whereas cumulative incidence was used to estimate TRM, GVHD and relapse. 14, 15 Cox multiple regression models were conducted for OS and DFS. Competing risk regression was employed for TRM, GVHD and risk of relapse. Age (o15 years vs X15-30 years) was the primary factor being considered for each end point in both univariate and multivariate regression. Other covariates used in the models included: number of prior remissions at the time of transplantation, gender, CMV status, BM versus UCB, HLA matching (in the case of double cord transplant, the matching of the engrafting cord was used), year of transplant and presence of high-risk biology. Neutrophil engraftment for this analysis was defined as three consecutive days with an ANC 4500/mL. The backward method was used to determine the final model with a P-value of p0.05 considered significant in all statistical tests. Statistical analysis was performed with Statistical Analysis System statistical software version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Neutrophil engraftment
Engraftment by day 42 after HCT occurred in 95% (95% confidence interval (CI) 90-98) of patients o15 years old and 88% (95% CI 79-95; P ¼ 0.03) of AYA patients. There were no differences in engraftment based on patient gender, disease status at the time of HCT, type of GVHD prophylaxis, CMV status, graft source or cytogenetic risk group. Engraftment was greater in patients who did not receive TBI conditioning (n ¼ 34) (100% vs 91%, 95% CI 85-95; Po0.01) and in those who did not report grade III-IV acute GVHD before engrafting (93%, 95% CI 88-96 vs 88%, 95% CI 58-99; P ¼ 0. 
OS and DFS
Comparing patients o15 years old with AYA using univariate analysis reported no significant difference in the 5-year OS (50%, 95% CI 40-59 vs 43%, 95% CI 35-59; P ¼ 0.89) or DFS (47%, 95% CI 37-57 vs 47%, 95% CI 35-59; P ¼ 0.89). This finding was confirmed in multivariate analysis that demonstrated similar OS (hazard ratio (HR) 0.90, 95% CI: 0.38-2.12; P ¼ 0.81) and DFS (HR 0.95, 95% CI: 0.62-1.45; P ¼ 0.80; Table 2 ). However, patients who were transplanted in CR1 had significantly greater OS (67%, 95% CI 54-77) and DFS (66%, 95% CI 53-76) as compared with those in either CR2 (OS: 49%, 95% CI 36-61; DFS: 47%, 95% CI 34-59) or CR3 (OS: 15%, 95% CI 6-29; Po0.01; DFS: 14%, 95% CI 5-26; Po0.01). After adjusting for disease status and other covariates in multivariate analysis, OS was no longer effected when comparing CR1 patients with CR2 (HR 1.42, 95% CI 0.57-3.57) or CR3 (HR 2.47, 95% CI 0.80-7.67; P ¼ 0.29). However, DFS retained significance (CR2: HR 1.70, 95% CI 1.00-2.90; CR3: HR 5.01, 95% CI 2.92-8.58; Po0.01).
When taking into account both age and CR status, patients o15 years old and in XCR2 had significantly worse 5-year OS compared with patients in CR1 (CR1: 74%, 95% CI 57-85 vs CR2: 54%, 95% CI 36-69 vs CR3: 7%, 95% CI 1-25; Po0.01), which was not observed for AYA patients (CR1: 58%, 95% CI 38-73 vs CR2: 43%, 95% CI 23-61 vs CR3: 30%, 95% CI 7-58; P ¼ 0.34). Similar findings were observed for EFS in younger patients with inferior survival related to more advanced disease (CR1: 72%, 95% CI 55-83 vs CR2: 51%, 95% CI 34-66 vs CR3: 7%, 95% CI 1-21; Po0.01; Figure 1a ). However, in AYA patients there was no difference in DFS based on their older age and CR status (CR1: 58%, 95% CI 38-73 vs CR2: 40%, 95% CI 21-58 vs CR3: 30%, 95% CI 7-58; P ¼ 0.33; Figure 1b) . 
TRM
In multivariate analysis there was a nonsignificant trend toward more TRM in older patients (relative risk 1.91, 95% CI 0.97-3.77; P ¼ 0.07; Table 2 ). TRM did not differ in patients based on remission status, HCT year, gender, graft source, presence of GVHD or pretransplant CMV seropositivity. Comparing TRM among the two primary graft sources separately (BM and UCB) revealed similar rates of TRM at 1 year (21%, 95% CI 13-30 vs 19%, 95% CI 10-28; respectively, P ¼ 0.69). Although year of HCT did not influence TRM for the entire cohort, when patients were stratified by age and year of transplant, patients o15 years of age (n ¼ 31) who received their HCT during 1995-1999 had significantly lower TRM as compared with AYA patients (n ¼ 21) (7%, 95% CI 0-16 vs 43%, 95% CI 21-64; Po0.01). There were no significant differences based on age and year of HCT for the periods of 2000-2004 (21%, 95% CI 7-64 vs 13%, 95% CI 0-28; P ¼ 0.44) or 2005-2010 (17%, 95% CI 5-30 vs 23%, 95% CI 8-38; P ¼ 0.55).
Causes of TRM for the AYA patients (n ¼ 19) included infection (n ¼ 5), organ failure (n ¼ 2), GVHD (n ¼ 1), graft failure (n ¼ 1) or missing data (n ¼ 10) compared with patients o15 years of age (n ¼ 19) who reported infection (n ¼ 4), organ failure (n ¼ 6), GVHD (n ¼ 1), graft failure (n ¼ 1), disease related (n ¼ 1) or missing data (n ¼ 7). GVHD Age (o15 vs 15-30 years) was a factor in the development of grade II-IV (31%, 95% CI 22-41 vs 48%, 95% CI 35-61; P ¼ 0.01) but not grade III-IV acute GVHD (15%, 95% CI 8-22 vs 20%, 95% CI 10-29; P ¼ 0.34). Similarly, age was associated with chronic GVHD (7%, 95% CI 2-12 vs 22%, 95% CI 12-33; Po0.01). In multivariate analyses, AYA AML patients continued to have greater grade II-IV acute GVHD by day 100 (HR 1.78, 95% CI 1.09-2.92; P ¼ 0.02) and chronic GVHD (HR 3.52, 95% CI 1.45-8.59; P ¼ 0.01). Patients who had prior acute GVHD reported significantly more chronic GVHD for both grades II-IV (24%, 95% CI 13-35 vs 7%, 95% CI 2-11; Po0.01) and grades III-IV (29%, 95% CI 12-46 vs 10%, 95% CI 5-15; P ¼ 0.01).
Among UCB recipients, AYAs were more likely to receive two units compared with younger patients (76% vs 43%) who predominantly received single UCB units (57% vs 24%; Po0.01). There was significantly greater grade II-IV (49%, 95% CI 34-64) and III-IV acute GVHD (29%, 95% CI 17-42) in recipients of double UCB as compared with single UCB units (29%, 95% CI 15-43; P ¼ 0.05; and 10%, 95% CI 1-18; P ¼ 0.03, respectively. There were no significant differences in the incidence of grade II-IV or III-IV acute GVHD in double UCB recipients based on age, with AYAs reporting similar rates as those o15 years of age (56%, 95% CI 35-77 vs 42%, 95% CI 23-62; P ¼ 0.20; and 36%, 95% CI 17-55 vs 23%, 95% CI 7-39; P ¼ 0.25, respectively. There were no differences in the incidence of grade II-IV or III-IV acute GVHD between the two age groups based on disease status, gender, presence of high-risk biology, graft source, GVHD prophylaxis, HLA-typing or year of HCT in either univariate or multivariate analyses.
Relapse There was no difference in the rate of relapse at 2 years between patients o15 years old and AYAs (24%, 95% CI 13-34 vs 33%, 95% CI 23-43; P ¼ 0.30; Figure 2 ). However, remission status did influence relapse as patients in CR1 (n ¼ 71) showed the lowest incidence (13%, 95% CI 5-20) compared with CR2 (n ¼ 60; 33%, 95% CI 21-46) or CR3 (n ¼ 37; 58%, 95% CI 38-77; Po0.01). Keeping age in the statistical model (o15 years vs AYA), disease status (CR1 vs CR2 vs XCR3) remained the most significant risk factor for relapse (CR2: relative risk 3.11, 95% CI 1.42-6.79; CR3: relative risk 6.57, 95% CI 2.95-14.62; Po0.01). Patients who reported grade II-IV acute GVHD had significantly lower relapse (18%, 95% CI 8-29 vs 35%, 95% CI 25-44; P ¼ 0.01) but there was no difference for grade III-IV acute GVHD (24%, 95% CI 7-41 vs 30%, 95% CI 22-38; P ¼ 0.35). In addition, relapse did not differ based on gender, TBI conditioning, GVHD prophylaxis, graft source, presence of high-risk cytogenetics, year of HCT or CMV seropositivity before transplant. Given these findings, as well as our recent study showing inferior outcomes after allo-HCT for AYA patients with ALL, 10 we hypothesized that similar results would be present in AYA AML patients undergoing allo-HCT. In this analysis of 168 patients, including children and AYA with AML who received a myeloablative allo-HCT between 1995 and 2010, we identified no differences in survival or relapse between children and AYA patients. We did observe a trend toward higher TRM in the AYA group. These findings are in contrast to our AYA ALL patient outcomes treated in a similar period, where higher TRM was reported that negatively affected DFS. 10 The reasons for these differences are not entirely clear but may reflect the fact that patients with ALL receive considerably more chemotherapy compared with AML patients. The typical duration of treatment for patients with ALL is 2-3 years, compared with 5-6 months for patients with AML, which may contribute to greater overall organ toxicity and TRM reported in patients receiving allo-HCT for ALL. In addition, patients with ALL are more likely to receive an allo-HCT in XCR2 as compared with AML where HCT in CR1 is more prevalent. As there were similar percentages of both ALL and AML AYA patients in CR1 (ALL 42% vs AML 48%) and XCR2 (ALL 58% vs AML 52%) in our reports, the differences in outcomes are likely not attributed to disease status at HCT.
Although induction/intensification therapies for AML are fairly similar between adult and pediatric groups, it is possible that subtle treatment approaches or timing of transplant referral may differ in the AYA group based on whether an adult or pediatric physician treated the patient. In this study, it was not possible to determine whether this factor (treatment by adult vs pediatric physicians) affected outcomes, and thus is a limitation to this study. However, the median age for the AYA group in our analysis was 22.6 years. Based on our hospital age policy (of treating patients up to age 24 years on the pediatric floor) during the time span of this report, we speculate a significant proportion (approximately half) of these patients were treated by pediatric providers and thus the potential differences in disease management between the AYA and younger age group should be nonsignificant.
Until recently, 9 there had been no analysis of AML HCT outcomes between children and AYA to identify differences in survival, relapse or TRM. Rubnitz et al. 4 reported on AML patients treated at St Jude Children's Research Hospital, who did not receive allo-HCT. These investigators described more survival and less TRM in younger-aged patients (o10 years old) as compared with older patients (10-20 years old). Particularly striking was the threefold increase in toxic death for older patients. The authors concluded that although treatment improvements have occurred over time to increase survival and limit relapse, toxic death rates in older-aged patients remain high. The Center for International Blood and Marrow Transplant Research (CIBMTR) recently reported AML outcomes for AYA compared with children and older adults. 9 In this analysis of 900 children (o15 years old), 2708 AYAs (15-40 years old) and 2728 older adults (440 years old), there were significant differences between children and AYAs with regard to OS, leukemia-free survival and TRM, favoring younger patients and year of allo-HCT, with outcomes improving in both groups over time. This analysis excluded UCB as a donor source, which was the primary graft source in our analysis.
The most significant differences that we identified between AYAs and o15-year-old AML patients who received an allo-HCT in this analysis were in the rates of GVHD for both grade II-IV acute and chronic. This was an expected finding as age in itself, both in the donor age and the recipient, has been previously identified as a risk factor for the development of acute GVHD. 16 Other reasons why AYAs may have reported higher rates of grade II-IV acute GVHD than younger patients could be because more of them received two UCB units compared with single UCB, which has been associated with less acute grade II-IV GVHD when compared with double umbilical cord blood transplantation. 17 Along with more AYAs receiving double umbilical cord blood grafts, PBSC was also used more frequently in these patients as compared with children, both of whom report higher rates of chronic GVHD. 18, 19 In summary, our retrospective analysis of children and AYAs who received an allo-HCT for AML identified similar survival regardless of age, with no increase in TRM or relapse in older patients. The difference in TRM between the two groups did trend toward worse outcomes for older patients, but our relatively low numbers may have limited the statistical significance of this finding. It is possible that through a larger analysis such as the CIBMTR, which includes UCB graft sources, differences in survival will be identified between younger patients and AYAs with AML receiving allo-HCT. Whether continued improvements in HCT supportive care, HLA typing and/or HCT conditioning regimens will further minimize TRM in AYA and increase OS in all patients is yet to be determined. Relapse. The cumulative incidence of relapse for patients o15 years of age was 33% compared with 24% for patients 15-30 years of age.
